In a targeted therapy context, metformin can synergistically enhance the in vitro and in vivo antiproliferative effects of CDK4/6 inhibition in experimental models of head and neck squamous cell carcinoma (HNSCC). The gene discussed is CDK4; the disease is head and neck squamous cell carcinoma.